论文部分内容阅读
生物技术药物近年来有很大发展,以美国为例,在临床中使用生物技术得到的药物到1996年已达184种,有113个公司参加了研究,美国FDA已批准了18个生物技术药物的申请(1),预计2000年生物技术产品产值可达亿美元以上的有红细胞生成素(EPO),粒细胞集落刺激因子(G-CSF),人生长激素(HGH),人胰岛素,α-干扰素,组织血纤维溶酶原活化剂(TPA),β-干扰素,血小板生成素,凝血因子Ⅲ等,其中EPO预测将成为世界年销
Biotech drugs have greatly developed in recent years. In the United States, for example, there are 184 kinds of drugs that have been clinically used in biotechnology. Of these, 113 companies participated in the study. The United States FDA has approved 18 biotech drugs (EPO), G-CSF, human growth hormone (HGH), human insulin, alpha-human insulin, and human insulin in 2000 with an estimated biotech product output of over US $ 100 million, Interferon, Tissue Plasminogen Activator (TPA), Beta Interferon, Thrombopoietin, Factor III, etc. Among them, EPO is predicted to become the world annual sales